CAS: 51934-41-9; Ethyl 4-Iodobenzoate

上下游产品

CAS号624-38-4 1,4-二碘苯 | CAS号109-94-4 甲酸乙酯 | CAS号619-58-9 对碘苯甲酸 | CAS号64-17-5 乙醇 | CAS号94-09-7 对氨基苯甲酸乙酯 | CAS号5798-75-4 4-溴苯甲酸乙酯 | CAS号131379-16-3 4-(乙氧羰基)苯基碘化锌 | CAS号125261-30-5 ethyl 4-(triflu... | CAS号902148-89-4 ethyl 4-(methan... | CAS号120-47-8 尼泊金乙酯 | CAS号10540-36-0 4'-FluoroBiphen... | CAS号10129-07-4 4-苯基磺酰基-苯甲酸乙酯 | CAS号5748-43-6 2’-甲基联苯-4-甲酸 | CAS号47230-38-6 4,4'-联苯二甲酸二乙酯 | CAS号19819-94-4 4-ALLYL-BENZOIC... | CAS号93-89-0 苯甲酸乙酯 | CAS号131379-16-3 4-(乙氧羰基)苯基碘化锌 | CAS号15165-27-2 4-CARBOETHOXYBE... | CAS号134-81-6 联苯甲酰 | CAS号2132-80-1 4,4-二甲氧基联苯

苯佐卡因置于二碘甲烷,Sodium Nitrite,溶剂黄146体系中,用 二氯甲烷,水 作为反应溶剂,化学反应 1.08H,以87%的收率获得产物对碘苯甲酸乙酯
参考文献:一锅,无金属地将苯胺转化为芳基溴化物和碘化物
标题:一锅,无金属地将苯胺转化为芳基溴化物和碘化物
摘要:描述了通过从溴代三氯甲烷和二碘代甲烷中提取卤素从苯胺无金属合成芳基溴化物和碘化物.该一锅法反应以中等至优异的收率从相应的苯胺提供了卤代芳基卤化物,而没有分离出重氮盐.该转化反应时间短,后处理简单,对湿气和空气不敏感,并且避免了过多的卤化.dft计算支持s Rn 1机制.此方法代表了经典sandmeyer反应的一种方便替代方法.
DOI:10.1021/acs.Orglett.7B00771

专利信息

专利号:US-8835476-B2
优先权日:2005-03-04
标 题:Synthesis of novel antimicrobials
发明人：WU FAN; WEAVER DONALD; BARDEN CHRIS; MCMASTER CHRISTOPHER; BYERS DAVID; HENNEBERRY ANNETTE; BAN FUQIANG
权利人:WU FAN; WEAVER DONALD; BARDEN CHRIS; MCMASTER CHRISTOPHER; BYERS DAVID; HENNEBERRY ANNETTE; BAN FUQIANG
摘要:The synthesis and activity of novel LpxA inhibitors is described, these inhibitors present antibacterial activity. The compounds were designed based on a receptor model developed using the crystal structure of LpxA and are arranged to have a favorable binding interaction at the active site of the enzyme. In particular, the compounds present the following formula (I) where V, W, X, Y and Z can be independently C, S, N or O and P1, P2 and P3 are ligands to bind to the three points of the proposed pharmacophore model. They can be chosen from a variety of groups.

专利号:US-2006069260-A1
优先权日:2004-09-28
标 题:Preparation of N-aryl pyridones
发明人：ZHANG HUIPING; CHEN BANG-CHI; ZHAO RULIN
权利人:ZHANG HUIPING; CHEN BANG-CHI; ZHAO RULIN
摘要:A novel process and intermediates thereof for making N-aryl pyridones of the type shown below from appropriate pyridinolates is described. n nThese compounds are useful as intermediates for the synthesis of clinical candidates.

专利号:US-7582771-B2
优先权日:2003-09-03
标题:Process for the synthesis of cPLA2 inhibitors
发明人：DEHNHARDT CHRISTOPH M; MEGATI SREENIVASULU; MICHALAK RONALD S; RAVEENDRANATH PANOLIL; REN JIANXIN; WU CHARLES C; WU YANGZHONG
权利人:WYETH CORP
摘要:A process for making the compound of formula (I) n nwherein Ac represents acetate; X represents O or CH 2 ; Y represents C 1 -C 6 alkyl; and Z is selected from the group consisting of H, halogen, CN, CHO, CF 3 , OCF 3 , OH, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 thioalkyl, NH 2 , N(C 1 -C 6 alkyl) 2 , NH(C 1 -C 6 alkyl), NC(O)—(C 1 C 6 alkyl), and NO 2 . In his process, a compound of formula (II)n n nis reacted with hydrazine to form a primary alkylamine, and then the primary alkylamine is reacted with acetic anhydride, to produce the compound of formula (I).

专利号:US-10647688-B2
优先权日:2014-12-19
标题:Compounds, synthesis method thereof and use of same in medicine and in cosmetics
发明人：PORTAL THIBAUD
权利人:GALDERMA RES & DEV
摘要:Novel compounds, synthesis methods and use of the same in medicine and in cosmetics are disclosed. Also disclosed, are novel compounds and ligands that modulate RARs.

专利号:US-6090810-A
优先权日:1995-09-01
标题:Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
发明人：KLEIN ELLIOTT S; JOHNSON ALAN T; STANDEVEN ANDREW M; BEARD RICHARD L; GILLETT SAMUEL J; DUONG TIEN T; NAGPAL SUNIL; VULIGONDA VIDYASAGAR; TENG MIN; CHANDRARATNA ROSHANTHA A
权利人:ALLERGAN SALES INC
摘要:Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity. These assays are based on the ability of negative hormones to down-regulate the activity of chimeric retinoid receptors engineered to possess a constitutive transcription activator domain.

专利号:US-5877207-A
优先权日:1996-03-11
标 题:Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
发明人：KLEIN ELLIOTT S; JOHNSON ALAN T; STANDEVEN ANDREW M; BEARD RICHARD L; GILLETT SAMUEL J; DUONG TIEN T; NAGPAL SUNIL; VULIGONDA VIDYASAGAR; TENG MIN; CHANDRARATNA ROSHANTHA A
权利人:ALLERGAN SALES INC
摘要:Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity. These assays are based on the ability of negative hormones to down-regulate the activity of chimeric retinoid receptors engineered to possess a constitutive transcription activator domain.